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Abstract
Aims/hypothesis The aim of this study was to assess the
association between lifelong cumulative glycaemia estimat-
ed by lens fluorometry and the presence of retinopathy in
individuals with type 2 diabetes.
Methods We carried out a cross-sectional population-based
study of 970 participants aged between 30 and 60 years, of
which 170 were diagnosed with diabetes on screening
(WHO 1999 criteria) and 35 had known type 2 diabetes.
Procedures included clinical and laboratory examinations,
non-invasive assessment of the intrinsic fluorescence of the
lens of the eye, and seven-field fundus photography.
Results Retinopathy was found in 46 (22%) of 205
participants with type 2 diabetes. In a logistic regression
analysis controlling for age, sex and diabetes status (screen-
detected or known), a two-fold increase in lens fluorescence
increased the odds for retinopathy by 3.46 (95% CI 1.25–
9.55, p=0.017). The association was marginally significant
(OR 3.00 [95% CI 1.00–9.01], p=0.050) when also
adjusted for smoking, systolic blood pressure, body mass
index and HbA1c.
Conclusions/interpretation Diabetic retinopathy was relat-
ed to cumulative lifelong glycaemia as estimated by lens
fluorometry in participants with type 2 diabetes. This
supports the hypothesis that retinopathy is a marker of
lifelong elevated glycaemia as well as of the unknown, pre-
diagnostic duration of type 2 diabetes. The powerful
association between lens fluorescence and retinopathy
underscores the importance of strict long-term glycaemic
control in the prevention of retinopathy in people with
diabetes.
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Abbreviations
ETDRS Early Treatment Diabetic Retinopathy Study
FPG Fasting plasma glucose
Introduction
A major challenge in the management of patients with
type 2 diabetes is that the disease can be asymptomatic for
many years until it is diagnosed following the appearance of
long-term complications. Risk factor analysis for complica-
tions of type 2 diabetes suffers from an inherent inability to
account for the duration of diabetes, which cannot be
assessed retrospectively. An index of lifelong cumulative
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glycaemia can be obtained by measuring fluorescence in the
lens of the eye. The bulk of the lens proteins are never lost or
replaced [1] and therefore accumulate fluorescent adducts in
proportion to age and glycaemia after glucose has reacted
with the lens protein amino residuals [2]. The same
spontaneous reaction leads to the formation of HbA1c [2].
Lens fluorescence has been shown to increase with age
[3], duration of diabetes [3, 4], glycaemia [5] and smoking
[6]. The presence of retinopathy in a clinic-based popula-
tion of patients with variable diabetes duration and type has
been found to be associated with higher levels of
fluorescence measured by a method not correcting for
intrinsic light absorption [4]. The aim of the present study
was to investigate if retinopathy is associated with lens
fluorescence in a population-based study of primarily newly
diagnosed individuals with type 2 diabetes.
Methods
Study participants were recruited from the baseline visit of
the Inter99 study, a randomised non-pharmacological inter-
vention study of ischaemic heart disease prevention [7]. An
age- and sex-stratified random sample of 12,934 eligible
individuals aged 30–60 years was invited to participate, of
whom 6,906 (53.4%) volunteered. In brief, the Inter99 Eye
study examined 970 participants from the Inter99 study
between 1999 and 2001, including a random sample of 563
participants and a skewed sample of 407 participants with a
high-risk profile defined by a compound cardiovascular risk
score [8]. Diabetes-related data were available for 937
participants. The present analysis excluded six participants,
three with type 1 diabetes (serum C-peptide <100 pmol/l)
and three with ungradeable or missing fundus photographs,
thus leaving 205 participants with type 2 diabetes for
analysis. In 17 participants lens fluorometry was unavail-
able (lens opacities in three, instrument failure in 14).
All participants gave their written informed consent. The
protocols were in accordance with the Helsinki Declaration
and approved by the local medical ethics committees. The
Inter99 study was registered in 2005 at ClinicalTrials.gov
(registration no. NCT00289237).
After pupil dilation, participants underwent an ophthal-
mic examination including cataract assessment and 7-field
non-stereoscopic 60-degree digital fundus photography
(TRC-50X camera; Topcon, Tokyo, Japan) with a 1,024×
1,024 pixel CV-1000 back-piece (AngioVision 1000,
MediVision, Tel Aviv, Israel) in red-free illumination
(Wratten 54 filter; Eastman Kodak, Rochester, NY, USA)
and fovea-centred stereoscopic colour diapositive photog-
raphy (Ektachrome Elite 100; Eastman Kodak). Fundus
characteristics were assessed by an ophthalmologist (I. C.
Munch) masked to all systemic variables. The photographs
were graded for retinal lesions and classified according to
the Early Treatment Diabetic Retinopathy Study (ETDRS)
retinopathy severity scale. The maximum grade in any of
the seven standard fields in either of a participant’s eyes
defined the participant’s retinopathy level.
Lens fluorescence was measured using a non-invasive
ocular fluorometer (Fluorotron, OcuMetrics, Mountain
View, CA, USA). Excitation was from 430 to 490 nm and
detection 530–630 nm. Lens fluorescence was measured
along the optical axis of the eye and measurements were
corrected for loss of light by absorption in the lens. The
mean of six scans, three per eye, was used in analysis. All
fluorescence values were calibrated to an external solution
of fluorescein and expressed as equivalent concentration of
fluorescein in ng/ml (ng f-eq/ml). The coefficient of
variation for repeated measurements of lens fluorescence
is below 3% [3].
Participants were defined as having diabetes mellitus
when fasting plasma glucose (FPG) was 7.0 mmol/l or
higher or when 2 h plasma glucose during the oral glucose
tolerance test was 11.1 mmol/l or higher or if participants
responded to the study questionnaire that they had been
diagnosed with diabetes by a physician.
The lower of two blood pressure recordings made after
at least 5 min of rest was used for data analysis. Smoking
was assessed by questionnaire, daily smoking being defined
as an average consumption of ≥7 g of tobacco per day for
more than 1 year.
Multiple logistic regression and general linear modelling
(proc LOGISTIC and GLM, SAS software package version
9.1, SAS institute, Cary, NC, USA) was used for data
analysis. Two-tailed p values and 95% CIs were calculated
by the use of Wald’s test. Trends were estimated as the
slope when categorical variables of interest were treated as
quantitative variables. Log-linear assumptions were tested
by likelihood ratio tests. Tests for interaction were
performed by adding the cross product to the model.
Results
The 970 participants in the Inter99 Eye Study included 205
individuals with type 2 diabetes who had complete retinop-
athy data. Of these, 170 (83%) had screen-detected diabetes
and 35 (17%) had known type 2 diabetes (Table 1). Some
retinopathy (ETDRS level ≥15) was found in 46 of the 205
participants (22%) and mild retinopathy or worse (ETDRS
level ≥35) was found in 10 of these 46 participants (4.9%
of all 205 participants with type 2 diabetes; Table 1).
Lens fluorescence was significantly associated with
retinopathy. In a logistic regression model adjusting for
age, sex and diabetes status (screen-detected or known), the
OR for the presence of retinopathy was 4.82 (95% CI 1.19–
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19.47) in participants in the top quartile of the lens
fluorescence distribution compared with participants in the
lowest quartile of the lens fluorescence distribution
(Table 2). Including the logarithm of lens fluorescence as
a quantitative trait in the model resulted in a better fit. A
twofold increase in lens fluorescence raised the odds of
having retinopathy by 3.46 (95% CI 1.25–9.55, p=0.017)
(Table 2). The effect of lens fluorescence on retinopathy
persisted in a multivariate analysis adjusting also for
smoking, systolic blood pressure, BMI and HbA1c, (OR
3.00 [95% CI 1.00–9.01, p=0.050] per twofold increase in
the level of lens fluorescence) (Table 2). The logarithm of
lens fluorescence increased with increasing HbA1c (p=
0.0055) when controlling for age, sex, diabetes status and
smoking (data not tabulated). No significant interaction
between lens fluorescence and other variables was observed
in any of the analyses.
The prevalence of retinopathy was higher in participants
with known diabetes (46%) than in participants with
screen-detected diabetes (18%) (Table 2). No significant
interaction was observed between diabetes status (known vs
screen-detected) and other tested variables. Female sex was
protective of retinopathy, the effect being largely unaltered
in the multivariate analysis (Table 2). Systolic blood
pressure was associated with the presence of retinopathy
and the association remained significant in a multivariate
analysis (Table 2).
Discussion
In the present study, lens fluorescence, a biomarker of
lifelong cumulative glycaemia, was independently associ-
ated with diabetic retinopathy in participants with type 2
diabetes.
The strengths of the study include the use of grey-scale
fundus photography and lens fluorometry based on a
scanning technique. A limitation was that ascertainment of
participants included a planned over-representation of
participants with screen-detected diabetes; however, the
effects of lens fluorescence and other risk factors on
retinopathy were found not to depend on diabetes status.
The power to exclude associations was limited by the total
of 46 participants with retinopathy.
A previous study also found associations between
retinopathy and lens fluorescence in eyes with clear lenses
in both early- and late-onset diabetes [4]. However, it was
not population-based and did not include information about
metabolic control or use a referenced method of retinopathy
grading.
There is well-established evidence that the presence of
retinopathy is an independent risk factor for systemic
vascular complications [9] in type 2 diabetes. It is of
interest for the understanding of diabetes to determine
whether this association is based on retinopathy being a
marker of the unknown pre-diagnostic duration and severity
of type 2 diabetes or on retinopathy being an independent
marker of vascular frailty. We found a strong association
between retinopathy and the level of lens fluorescence,
indicating that true duration of diabetes and hyperglycaemia
severity are important factors in the development of
retinopathy. Lens fluorescence may potentially be used in
future studies to account for the unknown pre-diagnostic
duration of type 2 diabetes.
Increased systolic blood pressure and high levels of
HbA1c are known risk factors for diabetic retinopathy [10]
but in this study only increased systolic blood pressure was
associated with retinopathy, either because study power was
limited or because lens fluorescence was a better glycaemia
biomarker. The prevalence of retinopathy was lower in
Table 1 Characteristics of included participants
Variable Inter99Eye Study participants
with type 2 diabetes (n=205)
Age (years) 51 (7.1)
Male/female (%) 60/40
Danish nationality (%) 97
BMI (kg/m2) 30.8 (6.0)
Systolic blood pressure (mmHg) 142 (18.1)
Diastolic blood pressure (mmHg) 88 (11.0)
Hypertension (%)a 92
Smoking daily (%) 38
Total cholesterol (mmol/l) 5.9 (1.1)
LDL-cholesterol (mmol/l) 3.8 (1.0)
Triacylglycerol (mmol/l) 1.8 (1.3)
Low HDL-cholesterolb (%) 41
HbA1c (%) 6.9 (1.6)
FPG (mmol/l) 7.1 (2.1)
Known diabetes (%) 17
Duration of known diabetes (years)c 4.0 (5.0)
Retinopathy [n (%)]:
ETDRS≥15 46 (22)
ETDRS≥35 10 (4.9)
Lens fluorescence (mg f-eq/ml) 673 (310)
Data are presented as mean (standard deviation) or proportions except
for triacylglycerol, FPG, duration of diabetes and lens fluorescence,
which are presented with median and interquartile range because of a
skewed distribution
a Hypertension is defined as systolic blood pressure ≥130 mmHg or
diastolic blood pressure ≥80 mmHg
b <1.0 mmol/l (40 mg/dl) in men and <1.3 mmol/l (50 mg/dl) in women
c Data from 33 participants with known type 2 diabetes and information on
the duration of diabetes
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Table 2 Lens fluorescence and other risk factors for retinopathy in participants with type 2 diabetes
Variable Retinopathya
cases/number of participants (%)
ORb (95% CI) ORc (95% CI)
Lens fluorescence
Per twofold increase 3.46 (1.25–9.55) 3.00 (1.00–9.01)
p value 0.017 0.050
1st quartile 5/47 (11) 1 1
2nd quartile 9/47 (19) 2.98 (0.78–11.33) 3.03 (0.79–11.67)
3rd quartile 10/47 (21) 3.21 (0.78–13.11) 2.88 (0.69–12.02)
4th quartile 16/47 (34) 4.82 (1.19–19.47) 3.69 (0.86–15.74)
p value for trend 0.043 0.13
Age (years)
30–39 3/19 (16) 1 1
40–49 15/67 (22) 1.07 (0.25–4.60) 0.37 (0.06–2.43)
50–60 28/119 (24) 1.19 (0.29-4.86) 0.29 (0.038–2.21)
p value for trend 0.74 0.35
Sex
Male 34/122 (28) 1 1
Female 12/83 (14) 0.35 (0.16–0.78) 0.31 (0.12–0.78)
p value 0.010 0.013
Status of diabetes
Screen-detected 30/170 (18) 1 1
Known 16/35 (46) 4.87 (2.14–11.11) 5.29 (1.75–15.97)
p value 0.0002 0.0031
Daily smoking
No 25/126 (20) 1 1
Yes 21/78 (27) 1.16 (0.56–2.41) 1.26 (0.53–2.98)
p value 0.68 0.61
Systolic blood pressure (mmHg)
<130 6/45 (13) 1 1
130–139 8/38 (21) 2.64 (0.73–9.49) 2.52 (0.61–10.34)
140–159 20/79 (25) 3.54 (1.14–11.02) 3.24 (0.89–11.85)
≥160 12/43 (28) 4.14 (1.22–14.02) 4.11 (1.03–16.37)
p value for trend 0.020 0.046
BMI (kg/m2)
<25 8/27 (30) 1 1
25–29 18/83 (22) 0.45 (0.15–1.31) 0.48 (0.14–1.64)
≥30 20/95 (21) 0.49 (0.17–1.37) 0.59 (0.16–2.11)
p value for trend 0.32 0.62
HbA1c (%)
<6.0 8/44 (18) 1 1
6.0–6.4 9/52 (17) 0.63 (0.21–1.92) 0.84 (0.26–2.69)
6.5–6.9 8/44 (18) 0.63 (0.20–2.00) 0.55 (0.14–2.12)
≥7.0 21/65 (32) 1.08 (0.38–3.01) 0.75 (0.23–2.51)
p value for trend 0.65 0.62
a Retinopathy defined as ETDRS level ≥15
b Adjusted for age, sex and diabetes status (known/screen-detected)
c Adjusted for all variables listed
760 Diabetologia (2011) 54:757–761
females compared with males. This may be a result of
women diagnosed with screen-detected diabetes being
healthier than their male counterparts, as the dose of
glucose in the oral glucose tolerance test is unadjusted for
differences in lean body weight.
In conclusion, this study provides evidence that diabetic
retinopathy is related to cumulative lifelong glycaemia. It
supports the hypothesis that retinopathy is a marker of
elevated lifelong glycaemia and hence of the unknown, pre-
diagnostic duration of type 2 diabetes. The powerful
associations between lens fluorescence and retinopathy
underscore the importance of strict glycaemic control in
the prevention of diabetic retinopathy.
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